SCHEMBL17840567

SCHEMBL17840567

COc1ccc(-c2c(-c3ccnc(NC(=O)CN4CCN(CCO)CC4)c3)[nH]c3cc(Cl)cnc23)cn1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 6/20 0.56
TGFBR2 P37173 4/20 0.56
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
BUB1 O43683 1/20 0.39
TBK1 Q9UHD2 3/20 0.38
PDE5A O76074 1/20 0.37
GSK3B P49841 5/20 0.37
DYRK1A Q13627 5/20 0.37
WNT1 P04628 4/20 0.37
BTK Q06187 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
FGFR3 P22607 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17840699 0.94 TGFBR1 (0.57) TGFBR1TGFBR2GSK3BDYRK1AWNT1
SCHEMBL17840808 0.92 TGFBR1 (0.57) TGFBR1TGFBR2KDM4EBUB1TBK1
SCHEMBL17840870 0.90 TGFBR1 (0.70) TGFBR1TGFBR2KDM4EHPGDHSD17B10
SCHEMBL17840945 0.90 TGFBR1 (0.57) TGFBR1TGFBR2GSK3BDYRK1AWNT1
SCHEMBL17863797 0.90 TGFBR1 (0.46) TGFBR1TGFBR2KDM4EHPGDHSD17B10
SCHEMBL17840954 0.87 TGFBR1 (0.56) TGFBR1TGFBR2KDM4EHPGDHSD17B10
SCHEMBL17840603 0.86 TGFBR1 (0.64) TGFBR1TGFBR2KDM4E
SCHEMBL17863801 0.84 TGFBR1 (0.54) TGFBR1TGFBR2KDM4EHPGDHSD17B10
SCHEMBL17840768 0.84 TGFBR1 (0.72) TGFBR1TGFBR2GSK3BDYRK1AWNT1
SCHEMBL17863817 0.84 TGFBR1 (0.47) TGFBR1TGFBR2KDM4EGSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3237415-A1 TGF RECEPTOR ANTAGONISTS Bristol-Myers Squibb Company (US) 2017-11-01 EP disclosed
US-9708316-B2 TGFβR antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2017-07-18 US disclosed
US-9708316-B2 TGFβR antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2017-07-18 US disclosed
WO-2016106266-A1 TGFβ RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-06-30 WO disclosed
WO-2016106266-A1 TGFβ RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-06-30 WO disclosed
US-20160176871-A1 TGF BETA R ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2016-06-23 US disclosed
US-20160176871-A1 TGF BETA R ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176871-A1 TGF BETA R ANTAGONISTS TGFBR2, TGFBR1, TGFB1 TGFBR1 2/4885TGFBR2 1/4885KDM4E 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.